Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Latest shares articles
USD/JPY drops below 156 as US CPI eases and BOJ rate hike expectations increase
An increase in rate hike expectations from the BOJ and softer US CPI data see USD/JPY turn lower
14:47, 16 January 2025
UK inflation cools in December, GBP/USD attempts to bounce back
UK inflation drops more than expected in December, easing some of the fears about the UK economy.
09:41, 15 January 2025
Market Analysis: EUR/GBP Extends Rally but Faces Key Resistance
A worsening economic outlook in the UK is driving the pound lower, pushing EUR/GBP to a two-and-a-half-month high.
14:56, 14 January 2025
AUD/USD hovers near five year low ahead of labour force data
Australia’s labour market is expected to have cooled in December, according to economist forecasts. The economy is projected to have added 15,000 jobs in the month, lifting the unemployment rate to 4.0%. The lukewarm estimate follows a drop in the unemployment rate to 3.9% in November, owing to a combination of strong full time employment growth and a drop in the participation rate.
12:25, 14 January 2025
Ratings and Reviews
Ratings and Reviews
